China
Africa
Explore chapters and articles related to this topic
The professional voice user
Published in Declan Costello, Guri Sandhu, Practical Laryngology, 2015
Throat irritation can be brought about through a variety of mechanisms. Approximately 20–25% of the western world suffers with allergy, allergic rhinitis and/or asthma. Information relating to the effects of allergy on the voice is still in its infancy38–42 but it does appear that it can play a role in voice problems, as can some of the medications prescribed (see below).
Features and impact of dysphagia, dysphonia and laryngeal hypersensitivity in whiplash associated disorder – a qualitative study
Published in Disability and Rehabilitation, 2023
Danielle B. Stone, Trudy Rebbeck, Elizabeth C. Ward, James E. Elliott
Alongside cough, numerous participants discussed the sensation of throat irritation. Many described a throat itch, while others reported more non-specific, uncomfortable sensations, for example “it’s a bit of like hitting like a nerve…it’s an uncomfortable feeling” (P7). Several spoke of feeling more conscious of their throat region. While many participants described throat tension associated with talking and eating, others reported it more generally, describing “restriction” at the level of the larynx (P11), tightness or even, the feeling of being “strangled” (P10). Participant 7 reported a specific and frequent sensation of the larynx “locking” or “popping” to one side. Like swallowing and voice, participants spoke of their belief that “the muscles are really tight around there (the throat)” (P9).
Current therapeutical strategies for allergic rhinitis
Published in Expert Opinion on Pharmacotherapy, 2019
Ludger Klimek, Annette Sperl, Sven Becker, Ralph Mösges, Peter Valentin Tomazic
With regard to clinical efficacy, GCSs can effectively improve all nasal symptoms, including the often difficult-to-treat nasal obstruction and reduced sense of smell [9,12]. These agents are generally well tolerated but may have local side effects such as epistaxis, nasal dryness, and throat irritation. Systemic side effects, such as those feared during oral or parenteral administration of GCSs, are extremely rare. Growth inhibition in children has so far been demonstrated only during treatment with beclomethasone dipropionate [26]. Other potential but rare risks of long-term GCS use include nasal bleeding, septal perforation, candidiasis, headache, cataract, and suppression of the hypothalamic-pituitary axis [27]. Nevertheless, children should be regularly monitored during long-term treatment [9]. In contrast to antihistamines, GCSs show maximal efficacy after an interval of up to 1–3 weeks. Therapy must therefore be started early and applied regularly, and it should not be used ‘as needed’ [9]. Due to their good efficacy profile, nasal GCSs are the first choice in the treatment of AR [9].
CD38 as an immunotherapeutic target in multiple myeloma
Published in Expert Opinion on Biological Therapy, 2018
Francesca Bonello, Mattia D’Agostino, Maria Moscvin, Chiara Cerrato, Mario Boccadoro, Francesca Gay
In the trials described above, daratumumab proved to be well tolerated, with the main toxicity consisting in IRRs (occurring in 42–71% of patients in clinical trials). IRRs are generally mild and limited to first administration. Treatment discontinuation due to IRRs is uncommon. Main symptoms involve the respiratory tract, with throat irritation, cough, and dyspnea. As mentioned above, the respiratory pattern of daratumumab-induced IRRs can be partially explained by CD38 expression by airway muscle cells. Besides standard premedication of mAbs administration with steroids, antihistamines, and antipyretics, the addition of a leukotriene receptor antagonist (montelukast) showed to be beneficial in preventing severe respiratory IRRs and it is therefore recommended in clinical practice. Delayed IRRs can be prevented by oral corticosteroid therapy for the 2 days following daratumumab infusion. Patients with severe pulmonary comorbidities, such as obstructive disease, are particularly at risk of developing severe respiratory IRRs and the risk–benefit balance of daratumumab therapy should be evaluated [45].